TY - JOUR AU - Fu, E.L. AU - Desai, R.J. AU - Paik, J.M. AU - Kim, D.H. AU - Zhang, Y. AU - Mastrorilli, J.M. AU - Cervone, A. AU - Lin, K.J. TI - Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - 83 PY - 2024 IS - 3 SP - 293 EP - 305.e1 SN - 0272-6386 DO - 10.1053/j.ajkd.2023.08.017 UR - https://m2.mtmt.hu/api/publication/34716168 ID - 34716168 N1 - Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, United States Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife and Harvard Medical School, Boston, Massachusetts, United States Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States Cited By :2 Export Date: 1 March 2024 CODEN: AJKDD Correspondence Address: Lin, K.J.; Division of Pharmacoepidemiology and Pharmacoeconomics, 1620 Tremont St, Suite 3030, United States; email: jklin@bwh.harvard.edu LA - English DB - MTMT ER - TY - JOUR AU - Ha, J.T. AU - Freedman, S.B. AU - Kelly, D.M. AU - Neuen, B.L. AU - Perkovic, V. AU - Jun, M. AU - Badve, S.V. TI - Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - 83 PY - 2024 IS - 3 SP - 350 EP - 359.e1 SN - 0272-6386 DO - 10.1053/j.ajkd.2023.07.023 UR - https://m2.mtmt.hu/api/publication/34514118 ID - 34514118 N1 - The George Institute for Global Health, Sydney, NSW, Australia Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia Department of Renal Medicine, St George Hospital, Sydney, NSW, Australia Heart Research Institute, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States Global Brain Health Institute, Trinity College Dublin, Ireland Export Date: 18 January 2024 CODEN: AJKDD Correspondence Address: Badve, S.V.; The George Institute for Global Health, Level 5, 1 King St, Australia; email: sbadve@georgeinstitute.org.au LA - English DB - MTMT ER - TY - JOUR AU - Mottl, A.K. AU - Nicholas, S.B. TI - KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - 83 PY - 2024 IS - 3 SP - 277 EP - 287 PG - 11 SN - 0272-6386 DO - 10.1053/j.ajkd.2023.09.003 UR - https://m2.mtmt.hu/api/publication/34512939 ID - 34512939 N1 - Export Date: 18 January 2024 CODEN: AJKDD Correspondence Address: Mottl, A.K.; University of North Carolina Kidney Center, CB# 7155, United States; email: amy_mottl@med.unc.edu LA - English DB - MTMT ER - TY - JOUR AU - Chaudhari, Juhi AU - Miao, Shiyuan AU - Lewis, Julia B. AU - Heerspink, Hiddo J. L. AU - Levey, Andrew S. AU - Inker, Lesley A. TI - Impact of Using the Race-Free 2021 CKD-EPI Creatinine Equation on Treatment Effects on GFR-Based End Points in Clinical Trials JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - 83 PY - 2024 IS - 2 SP - 269 EP - 272 PG - 4 SN - 0272-6386 DO - 10.1053/j.ajkd.2023.05.012 UR - https://m2.mtmt.hu/api/publication/34733128 ID - 34733128 LA - English DB - MTMT ER - TY - JOUR AU - Srivastava, A. AU - Schmidt, I.M. AU - Palsson, R. TI - Combined Angiotensin Inhibition for CKD: The Truth Is Rarely Pure and Never Simple JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - 83 PY - 2024 IS - 2 SP - 130 EP - 132 PG - 3 SN - 0272-6386 DO - 10.1053/j.ajkd.2023.10.003 UR - https://m2.mtmt.hu/api/publication/34716943 ID - 34716943 N1 - Division of Nephrology, Department of Medicine, University of Illinois Chicago, Chicago, Illinois, United States Section of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States Hamburg Center for Kidney Health, University Medical Center Hamburg, Hamburg, Germany Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States Export Date: 2 March 2024 CODEN: AJKDD Correspondence Address: Palsson, R.; Massachusetts General Hospital Transplant Center, 165 Cambridge St, Suite 302, United States; email: rpalsson1@bwh.harvard.edu LA - English DB - MTMT ER - TY - JOUR AU - Ebert, Thomas AU - Sattar, Nosheen AU - Greig, Marni AU - Lamina, Claudia AU - Froissart, Marc AU - Eckardt, Kai -Uwe AU - Floege, Jorgen AU - Kronenberg, Florian AU - Stenvinkel, Peter AU - Wheeler, David C. AU - Fotheringham, James TI - Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - 83 PY - 2024 IS - 1 SP - 18 EP - 27 PG - 10 SN - 0272-6386 DO - 10.1053/j.ajkd.2023.05.010 UR - https://m2.mtmt.hu/api/publication/34626917 ID - 34626917 LA - English DB - MTMT ER - TY - JOUR AU - Platt, Alyssa AU - Wilson, Jonathan AU - Hall, Rasheeda AU - Ephraim, Patti L. AU - Morton, Sarah AU - Shafi, Tariq AU - Weiner, Daniel E. AU - Boulware, L. Ebony AU - Pendergast, Jane AU - Scialla, Julia J. TI - Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - 83 PY - 2024 IS - 1 SP - 58 EP - 70 PG - 13 SN - 0272-6386 UR - https://m2.mtmt.hu/api/publication/34612137 ID - 34612137 AB - Rationale & Objective: Optimal approaches treat secondary hyperparathyroidism (SHPT) patients on maintenance hemodialysis (HD) have yet to be established in randomized controlled trials (RCTs). Study Design: Two observational clinical trial emulations. Setting & Participants: Both emulations included adults receiving in-center HD from a national dialysis organization. The patients who had SHPT in the period between 2009 and 2014, were insured for >_180 days by Medicare as primary payer, and did not have contraindications or poor health status limiting theoretical trial participation.Exposure: The parathyroid hormone (PTH) Target Trial emulation included patients with new-onset SHPT (first PTH 300-600 pg/mL), with 2 arms defined as up-titration of either vitamin D sterols or cinacalcet within 30 days (lower target) or up-titration (higher target). The Agent Trial emulation included patients with a PTH >_300 pg/mL while on >_6 mu g weekly of vitamin D sterol (paricalcitol equivalent dose) and no prior history of cinacalcet. The 2 arms were defined by the first dose or agent change within 30 days (vitamin D-favoring [vitamin-D was up-titrated] cinacalcet-favoring [cinacalcet was added] nondefined [neither applies]). Multiple trials patient were allowed in trial 2.Outcome: The primary outcome was all-cause death over 24 months; secondary outcomes included cardiovascular (CV) hospitalization or the composite of CV hospitalization or death. Analytical Approach: Pooled logistic regression. Results: There were 1,152 patients in the PTH Target Trial (635 lower target and 517 higher target). There were 2,726 unique patients with 6,727 patient trials in the Agent Trial (6,268 vitamin D-favoring trials and 459 cinacalcetfavoring trials). The lower PTH target approach was associated with reduced adjusted hazard of death (HR, 0.71 [95% CI, 0.52-0.93]), CV hospitalization (HR, 0.78 [95% CI, 0.63-0.9 8]), and their composite (HR, 0.74 [95% CI, 0.61-0.8 9]). The cinacalcet-favoring approach demonstrated lower adjusted hazard of death compared to the vitamin D-favoring approach (HR, 0.79 [95% CI, 0.62-0.9 9]), but not of CV hospitalization or the composite outcome. Limitations: Potential for residual confounding; low use of cinacalcet with low power. Conclusions: SHPT management that is focused on lower PTH targets may lower mortality and CV disease in patients receiving HD. These findings should be confirmed in a pragmatic randomized trial. LA - English DB - MTMT ER - TY - JOUR AU - Kearney, Andrew O. AU - Lerma, Edgar AU - Lin, Jennie TI - Building Toward Clinical Translation: New Study Refines Genetic Architecture of IgA Nephropathy JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - 83 PY - 2024 IS - 1 SP - 108 EP - 111 PG - 4 SN - 0272-6386 DO - 10.1053/j.ajkd.2023.09.001 UR - https://m2.mtmt.hu/api/publication/34600511 ID - 34600511 N1 - Export Date: 28 February 2024; CODEN: AJKDD LA - English DB - MTMT ER - TY - JOUR AU - Kiernan, E.A. AU - Hu, D. AU - Philbrook, H.T. AU - Ix, J.H. AU - Bonventre, J.V. AU - Coca, S.G. AU - Moledina, D.G. AU - Fried, L.F. AU - Shlipak, M.G. AU - Parikh, C.R. TI - Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS PY - 2023 SN - 0272-6386 DO - 10.1053/j.ajkd.2023.07.012 UR - https://m2.mtmt.hu/api/publication/34259416 ID - 34259416 N1 - Division of Nephrology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States Division of Nephrology-Hypertension, University of California–San Diego, San Diego, California, United States Veterans Affairs San Diego Healthcare System, San Diego, CA, United States Kidney Health Research Collaborative, Department of Medicine, University of California–San Francisco, San Francisco, California, United States Renal Division, Brigham & Women's Hospital, Boston, Massachusetts, United States Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States Section of Nephrology and Clinical and Translational Research Accelerator, Department of Internal Medicine, School of Medicine, Yale University, New Haven, Connecticut, United States Renal Section, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, United States Export Date: 6 November 2023 CODEN: AJKDD Correspondence Address: Parikh, C.R.; Johns Hopkins University School of Medicine, 1830 E Monument St, Ste 416, United States; email: chirag.parikh@jhmi.edu Funding details: National Institutes of Health, NIH, K23DK117065, P30DK079310, R01DK093770, R01DK128087, R01HL085757, U01DK106962, U01DK114866, U01DK129984 Funding details: National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, R37DK39773, RO1DK072381, U01DK085660, U01DK102730 Funding details: Boehringer Ingelheim, BI Funding details: Office of Research and Development, ORD Funding details: Johns Hopkins University, JHU Funding text 1: Elizabeth A. Kiernan, MD, David Hu, MS, Heather Thiessen Philbrook, MMath, Joachim H. Ix, MD, MAS, Joseph V. Bonventre, MD, PhD, Steven G. Coca, DO, MS, Dennis G. Moledina, MD, PhD, Linda F. Fried, MD, MPH, Michael G. Shlipak, MD, MPH, and Chirag R. Parikh, MD, PhD. Research idea and study design: EK, HTP, SGC, CRP; data acquisition: CRP, LFF; data analysis/interpretation: DH, HTP, CRP; statistical analysis: DH, HTP; biomarker measurements: CRP, JVB; supervision or mentorship: JI, SGC, DGM, LFF, MGS, CRP. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. Dr Parikh is supported by NIH grants R01HL085757, U01DK114866, U01DK106962, U01DK129984, and R01DK093770, and P30DK079310. Dr Moledina is supported by K23DK117065 and R01DK128087. Drs Ix and Shlipak are supported by NIH/NIDDK U01DK102730. Dr Bonventre is supported by U01DK085660, RO1DK072381, and R37DK39773. The funders of this study had no role in current study design, collection, analysis or interpretation of the data, writing of the report, or decision to submit the report for publication. Drs Coca and Parikh are members of the advisory board of Renalytix and own equity in the same. Dr Parikh serves as a consultant for Genfit. Dr Coca has received consulting fees from Renalytix, Nuwellis, Takeda Pharmaceuticals, Vifor, 3ive, Reprieve Cardiovascular, Axon Therapies, Bayer, and Boehringer-Ingelheim. Drs Moledina and Parikh are co-inventors of the pending patent application “Methods and Systems for Diagnosis of Acute Interstitial Nephritis.” Dr Bonventre is cofounder and holds equity in Goldfinch Bio and Autonomous Medical Devices; is co-inventor on KIM-1 patents assigned to MassGeneralBrigham; has received consulting income and/or equity from Aldeyra, AstraZenica, Biomarin, Cadent, Citrine, DxNow, Goldilocks, MediBeacon, PTC, Praxis, Renalytix, Sarepta, and Seagen, and laboratory support from Kantum Pharma; has equity in Pacific Biosciences; and his interests are reviewed and managed by BWH and MGB in accordance with their conflict-of-interest policies. The other authors declare that they have no relevant financial interests. CSP# 565 Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D) was conducted and supported by the Department of Veterans Affairs Cooperative Studies Program (VACSP), Office of Research and Development. We thank the participants of the VA NEPHRON-D trial. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This analysis was carried out by the listed authors utilizing data that was specified and obtained under the Data Use Agreement (DUA) between VACSP and Johns Hopkins University, dated 01/09/2019. All statements, opinions, or views are solely of the author(s) and do not reflect official views of VA. Received October 13, 2022. Evaluated by 2 external peer reviewers, with direct editorial input from 2 Statistics/Methods Editors, an Associate Editor, and a Deputy Editor who served as Acting Editor-in-Chief. Accepted in revised form July 2, 2023. The involvement of an Acting Editor-in-Chief was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies. Funding text 2: Dr Parikh is supported by NIH grants R01HL085757, U01DK114866, U01DK106962, U01DK129984, and R01DK093770, and P30DK079310. Dr Moledina is supported by K23DK117065 and R01DK128087. Drs Ix and Shlipak are supported by NIH/NIDDK U01DK102730. Dr Bonventre is supported by U01DK085660, RO1DK072381, and R37DK39773. The funders of this study had no role in current study design, collection, analysis or interpretation of the data, writing of the report, or decision to submit the report for publication. Funding text 3: CSP# 565 Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D) was conducted and supported by the Department of Veterans Affairs Cooperative Studies Program (VACSP), Office of Research and Development. We thank the participants of the VA NEPHRON-D trial. AB - Rationale & Objective: Urinary biomarkers of injury, inflammation, and repair may help phenotype acute kidney injury (AKI) observed in clinical trials. We evaluated the differences in biomarkers between participants randomized to monotherapy or to combination renin-angiotensin-aldosterone system (RAAS) blockade in VA NEPHRON-D, where an increased proportion of observed AKI was acknowledged in the combination arm. Study Design: Longitudinal analysis. Setting & Participants: A substudy of the VA NEPHRON-D trial. Predictor: Primary exposure was the treatment arm (combination [RAAS inhibitor] vs monotherapy). AKI is used as a stratifying variable. Outcome: Urinary biomarkers, including albumin, EGF (epidermal growth factor), MCP-1 (monocyte chemoattractant protein-1), YKL-40 (chitinase 3-like protein 1), and KIM-1 (kidney injury molecule-1). Analytical Approach: Biomarkers measured at baseline and at 12 months in trial participants were compared between treatment groups and by AKI. AKI events occurring during hospitalization were predefined safety end points in the original trial. The results were included in a meta-analysis with other large chronic kidney disease trials to assess global trends in biomarker changes. Results: In 707 participants followed for a median of 2.2 years, AKI incidence was higher in the combination (20.7%) versus the monotherapy group (12.7%; relative risk [RR], 1.64 [95% CI, 1.16-2.30]). Compared with the monotherapy arm, in the combination arm the urine biomarkers at 12 months were either unchanged (MCP-1: RR, −3% [95% CI, −13% to 9%], Padj = 0.8; KIM-1: RR, −10% [95% CI, −20% to 1%], Padj = 0.2; EGF, RR −7% [95% CI, −12% to −1%], Padj = 0.08) or lower (albuminuria: RR, −24% [95% CI, −37% to −8%], Padj = 0.02; YKL: RR, −40% to −44% [95% CI, −58% to −25%], Padj < 0.001). Pooled meta-analysis demonstrated reduced albuminuria in the intervention arm across 3 trials and similar trajectories in other biomarkers. Limitations: Biomarker measurement was limited to 2 time points independent of AKI events. Conclusions: Despite the increased risk of serum creatinine–defined AKI, combination RAAS inhibitor therapy was associated with unchanged or decreased urinary biomarkers at 12 months. This suggests a possible role for kidney biomarkers to further characterize kidney injury in clinical trials. Plain-Language Summary: The VA NEPHRON-D trial investigated inhibition of the renin-angiotensin-aldosterone system (RAAS) hormonal axis on kidney outcomes in a large population of diabetic chronic kidney disease patients. The trial was stopped early due to increased events of serum creatinine–defined acute kidney injury in the combination therapy arm. Urine biomarkers can serve as an adjunct to serum creatinine in identifying kidney injury. We found that urinary biomarkers in the combination therapy group were not associated with a pattern of harm and damage to the kidney, despite the increased number of kidney injury events in that group. This suggests that serum creatinine alone may be insufficient for defining kidney injury and supports further exploration of how other biomarkers might improve identification of kidney injury in clinical trials. © 2023 The Authors LA - English DB - MTMT ER - TY - JOUR AU - Steinbrink, J.M. AU - Narayanasamy, S. AU - Wolfe, C.R. AU - Maziarz, E. AU - Byrns, J. AU - Kiser, J.J. AU - Naggie, S. TI - Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases JF - AMERICAN JOURNAL OF KIDNEY DISEASES J2 - AM J KIDNEY DIS VL - In press PY - 2023 PG - 5 SN - 0272-6386 DO - 10.1053/j.ajkd.2022.12.006 UR - https://m2.mtmt.hu/api/publication/34082934 ID - 34082934 LA - English DB - MTMT ER -